Your browser doesn't support javascript.
loading
Brain metabolite levels in remitted psychotic depression with consideration of effects of antipsychotic medication.
Tani, Hideaki; Moxon-Emre, Iska; Forde, Natalie J; Neufeld, Nicholas H; Bingham, Kathleen S; Whyte, Ellen M; Meyers, Barnett S; Alexopoulos, George S; Hoptman, Matthew J; Rothschild, Anthony J; Uchida, Hiroyuki; Flint, Alastair J; Mulsant, Benoit H; Voineskos, Aristotle N.
Afiliação
  • Tani H; Centre for Addiction and Mental Health and Department of Psychiatry, Temerty Faculty of Medicine, University of Toronto, Toronto, Canada.
  • Moxon-Emre I; Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.
  • Forde NJ; Centre for Addiction and Mental Health and Department of Psychiatry, Temerty Faculty of Medicine, University of Toronto, Toronto, Canada.
  • Neufeld NH; Centre for Addiction and Mental Health and Department of Psychiatry, Temerty Faculty of Medicine, University of Toronto, Toronto, Canada.
  • Bingham KS; Department of Cognitive Neuroscience, Donders Institute for Brain, Cognition and Behaviour, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands.
  • Whyte EM; Centre for Addiction and Mental Health and Department of Psychiatry, Temerty Faculty of Medicine, University of Toronto, Toronto, Canada.
  • Meyers BS; University Health Network and Department of Psychiatry, Temerty Faculty of Medicine, University of Toronto, Toronto, Canada.
  • Alexopoulos GS; Department of Psychiatry, University of Pittsburgh School of Medicine and UPMC Western Psychiatric Hospital, Pittsburgh, PA, USA.
  • Hoptman MJ; Department of Psychiatry, Weill Medical College of Cornell University and New York Presbyterian Hospital, White Plains, NY, USA.
  • Rothschild AJ; Department of Psychiatry, Weill Medical College of Cornell University and New York Presbyterian Hospital, White Plains, NY, USA.
  • Uchida H; Nathan Kline Institute for Psychiatric Research, Orangeburg, NY, USA.
  • Flint AJ; Department of Psychiatry, New York University School of Medicine, New York, NY, USA.
  • Mulsant BH; University of Massachusetts Medical School and UMass Memorial Health Care, Worcester, MA, USA.
  • Voineskos AN; Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.
Brain Imaging Behav ; 18(1): 117-129, 2024 Feb.
Article em En | MEDLINE | ID: mdl-37917311
ABSTRACT

BACKGROUND:

The neurobiology of psychotic depression is not well understood and can be confounded by antipsychotics. Magnetic resonance spectroscopy (MRS) is an ideal tool to measure brain metabolites non-invasively. We cross-sectionally assessed brain metabolites in patients with remitted psychotic depression and controls. We also longitudinally assessed the effects of olanzapine versus placebo on brain metabolites.

METHODS:

Following remission, patients with psychotic depression were randomized to continue sertraline + olanzapine (n = 15) or switched to sertraline + placebo (n = 18), at which point they completed an MRS scan. Patients completed a second scan either 36 weeks later, relapse, or discontinuation. Where water-scaled metabolite levels were obtained and a Point-RESolved Spectroscopy sequence was utilized, choline, myo-inositol, glutamate + glutamine (Glx), N-acetylaspartate, and creatine were measured in the left dorsolateral prefrontal cortex (L-DLPFC) and dorsal anterior cingulate cortex (dACC). An ANCOVA was used to compare metabolites between patients (n = 40) and controls (n = 46). A linear mixed-model was used to compare olanzapine versus placebo groups.

RESULTS:

Cross-sectionally, patients (compared to controls) had higher myo-inositol (standardized mean difference [SMD] = 0.84; 95%CI = 0.25-1.44; p = 0.005) in the dACC but not different Glx, choline, N-acetylaspartate, and creatine. Longitudinally, patients randomized to placebo (compared to olanzapine) showed a significantly greater change with a reduction of creatine (SMD = 1.51; 95%CI = 0.71-2.31; p = 0.0002) in the dACC but not glutamate + glutamine, choline, myo-inositol, and N-acetylaspartate.

CONCLUSIONS:

Patients with remitted psychotic depression have higher myo-inositol than controls. Olanzapine may maintain creatine levels. Future studies are needed to further disentangle the mechanisms of action of olanzapine.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antipsicóticos / Encéfalo / Depressão Limite: Humans Idioma: En Revista: Brain Imaging Behav Assunto da revista: CEREBRO / CIENCIAS DO COMPORTAMENTO / DIAGNOSTICO POR IMAGEM Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Canadá

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antipsicóticos / Encéfalo / Depressão Limite: Humans Idioma: En Revista: Brain Imaging Behav Assunto da revista: CEREBRO / CIENCIAS DO COMPORTAMENTO / DIAGNOSTICO POR IMAGEM Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Canadá